. In vitro inhibition of FGFR1 by FIIN-1 and FRIN-1 examined using the Z'-lyte assay The in vitro potency of the inhibitors was examined in the presence and absence of 6 mM DTT. Inhibitors were pre-incubated for 30 min before kinase reaction. Recombinant catalytic domain of FGFR1 (8 ng) was used and each data point was duplicated. IC 50 values were calculated using GraphPad Prism 4 software.
. In vitro inhibition of FGFR1 by FIIN-1 and FRIN-1 examined using the Z'-lyte assay The in vitro potency of the inhibitors was examined in the presence and absence of 6 mM DTT. Inhibitors were pre-incubated for 30 min before kinase reaction. Recombinant catalytic domain of FGFR1 (8 ng) was used and each data point was duplicated. IC 50 values were calculated using GraphPad Prism 4 software. Figure S2 . Time-course study of FGFR1-labeling and inhibition of FGFR1 in vitro (A) Recombinant catalytic domain FGFR1 (75 ng) was pre-incubated with FIIN-1-biotin (250 nM, approximately 1:2 ratio of enzyme:probe) for the indicated time and kinase activity was measured using the Z'-lyte assay for 1 hour at room temperature. Each assay was duplicated (red line in the chart). The assay mixture was also loaded to SDS-PAGE and biotin-labeling was measured using streptavidin-HRP blot (right). The intensity was quantified and presented in the chart (blue line). (B) Recombinant FGFR1 (8 ng) was pre-incubated with inhibitors (100 nM) for indicated time and activity was measured using the Z'-lyte assay (n = 2). The enzyme activity was inhibited by FIIN-1 more rapidly than by FRIN-1. (C) Labeling was examined for prolonged times up to 24 hours and labeling intensity was quantified. Gradual drug-labeling of FGFR1 was observed.
Figure S3, related to Figure 3. FRIN-1 reversibly inhibits iFGFR1
(A) MCF10A cells that express iFGFR1 were serum-starved for 16 hours and stimulated by AP20187 (100 nM) for indicated time.
(B) Serum-starved WT iFGFR1 MCF10A cells were pre-treated with the inhibitors (20 nM) for 1 hour, extensively washed, and incubated in a serum-free condition for 6 hours prior to iFGFR1 activation by AP20187 for 30 min. The reversible inhibitor FRIN-1 significantly lost its ability to inhibit autophosphorylation of iFGFR1 and downstream phosphorylation of Erk1/2 after wash-out while the irreversible inhibitor, FIIN-1, was able to maintain inhibition. Figure S4 . A number of intracellular proteins are irreversibly labeled by FIIN-1-biotin Biotinylated inhibitors (50 M) were incubated with extracts of iFGFR1 MCF10A cells followed by pulldown using streptavidin beads as described in Supplementary Procedures. The enriched streptavidin beads were divided into two fractions. One fraction (15% of total beads) was subjected to boiling in the presence of sample buffer and SDS-PAGE analysis. (A) Silver staining detected specific proteins bound to FIIN-1. (B) Streptavidin-HRP blot indicated the FIIN-1-biotin labeling of the enriched proteins. The remaining fraction of beads (85% of total beads) for each sample was subjected to an on-bead tryptic digestion and MS analysis. The proteins identified from the MS analysis are listed in Table S3 . hours. After the mixture was cooled down, it was filtered through celite. After removal of solvents in filtrate, the residue was basified with aq. sodium bicarbonate. The crude product was extracted with ethyl acetate (30 mL) twice. The organic layer was separated, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography with 10:1 dichloromethane-methanol (2% TEA) to afford the title compound as light brown solid (0.28 g, 85% 
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Cell cultures
MFE-296, AN3CA, Hec-1B cells were maintained in 40% RPMI1640, 40% DMEM, 20% FBS, 2 mM L-glutamine, and penicillin-streptomycin. HEK293 cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, and penicillin-streptomycin. 293-GPG cells were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 10 mM HEPES, 1 g/mL tetracycline (Sigma), 2 g/mL puromycin, 0.3 mg/mL G418 (Sigma), and penicillinstreptomycin. During retroviral transfection, cells were maintained in DMEM, 10% FBS, 10 mM HEPES, 2 mM L-glutamine, and penicillin-streptomycin. MCF10A cells were cultured in DMEM/F-12 supplemented with 5% horse serum (Gibco), 20 ng/mL epidermal growth factor (R&D Systems), 10 μg/mL insulin (Sigma), 100 μg/mL hydrocortisone (Sigma), 1 ng/mL cholera toxin (Sigma), and penicillin-streptomycin. Tel-kinase transformed Ba/F3 cells were cultured in RPMI1640 supplemented with 10% FBS, 2 mM L-glutamine, and penicillinstreptomycin. Mouse IL-3 was supplemented to culture media for WT Ba/F3 cells. HEK293 cells were transiently transfected with a full-length FGFR1 vector using Lipofectamine and Plus TM reagents (Invitrogen) for 2 days.
Retroviral transduction
Hemagglutinin (HA)-tagged mouse iFGFR1 cDNA (Welm et al., 2002) was subcloned into the pBABE-Puro retroviral vector (Cell Biolabs) as described (Xian et al., 2005) . The retroviral expression plasmids were transiently transfected into 293-GPG retroviral packaging cell line (Ory et al., 1996) using Lipofectamine 2000 (Invitrogen). After 72 hours, supernatants were collected in every 24 hours for 4 days and the combined virus-containing media was filtered through 0.45 m filter. Stable MCF10A cells expressing the iFGFR1 were generated by retroviral transduction in the presence of 8 g/mL polybrene (Sigma) followed by selection with 2 μg/mL puromycin (Sigma).
Generation of iFGFR1 C486S expression construct
Site-directed mutagenesis (C486S, TGC → TCC) of mouse iFGFR1 construct was performed using QuickChange 
Immunoprecipitation
Cells were then treated with each biotin probe for 3 hours, washed with a cold PBS twice, and harvested in a cold lysis buffer containing 10 mM phosphate buffer pH 8.0, 2 mM EDTA, 2 mM NaF, 2 mM Na 3 VO 4 , 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, Lammli sample buffer and subjected to SDS-PAGE. Biotin labeling was examined by streptavidin-HRP (Amersham) blot analysis and ECL detection (GE Healthcare).
Streptavidin pulldown experiment
Cell lysates (2 mg total proteins) were incubated with biotinylated probes (50 M, 0.5% volumes of TBS (10 mM Tris HCl pH 7.4, 150 mM NaCl) to make the concentration of SDS be 0.2%, and mixed with streptavidin beads (100 L, Sigma). Following incubation at RT for 2 hours, beads were extensively washed with three sequential washing steps: TBS + 0.2% SDS (10 mL), TBS + 6 M urea (10 mL), and TBS (10 mL). During each washing, beads in the washing buffers were rotated at RT for 15 min. From the biotin-enriched beads, a small fraction (15%) beads were boiled in the presence of 2x Lammli sample buffer and the eluted proteins were analyzed by SDS-PAGE, silver staining, and streptavidin-HRP blot. The rest (85%) beads were subjected to on-bead trypsin digestion and MS analysis.
Three-dimensional (3D) culture
The 3D culture of MCF10A cells were carried out as described (Debnath et al., 2003) .
Briefly, 5 x 10 3 cells were resuspended in growth medium containing 2% Matrigel (BD Biosciences) and seeded on top of a layer of growth factor-reduced Matrigel. Medium was changed every 4 days. Immunostaining was done as described (Debnath et al., 2003) .
On-bead trypsin digestion
The enriched streptavidin beads were mixed with 6 M urea (0.5 mL) and 200 mM TCEP 
MS analysis
The peptide solution was dried by vacuum centrifugation to about 20 L, and acidified with 10% TFA. Half of this solution was analyzed by automated nanoLC/ESI/MS using a Waters NanoAcquity UPLC system (Waters, Milford, MA) and a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap XL, ThermoFisher Scientific, San Jose, CA) as described with some modifications (Ficarro et al., 2009 ). Peptides were loaded on a precolumn (100 μm I.D. packed
